Condition: Unresectable Gastrointestinal Stromal Tumor (GIST) · Locally Advanced Gastrointestinal Stromal Tumor (GIST) · Metastatic Gastrointestinal Stromal Tumor · Sponsor: Centre Leon Berard
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease progression),sunitinib and regorafenib (either disease progression or intolerance) In the first arm, patients will be treated with imatinib + atezolizumab (experimental arm), whereas in the second arm, patients will be treated with imatinib alone (control arm). The comparison between this two arms will allow to compare whether or not atezolizumab and imatinib is efficient for disease control, in terms of Progression-Free Survival improvement.
This description comes directly from the study's public registry record.
Julien GAUTIER · +33 4 26 55 68 29 · julien.gautier@lyon.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Léon Bérard | Lyon, Rhône, France | Recruiting |
| Institut Bergonié | Bordeaux, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Hôpital de La Timone | Marseille, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| CHU Poitiers | Poitiers, France | Recruiting |
| Hôpital Robert Debré | Reims, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Recruiting |
| Institut de cancérologie de l'Ouest | Saint-Herblain, France | Recruiting |
| Centre Paul Strauss | Strasbourg, France | Not Yet Recruiting |
| ICANS CHRU de Strasbourg | Strasbourg, France | Terminated |
| Chru Tours | Tours, France | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05152472